Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort

Plevris N.; Chuah C. S.; Allen R. M.; Arnott I. D.; Brennan P. N.; Chaudhary S.; Churchhouse A. M. D.; Din S.; Donoghue E.; Gaya D. R.; Groome M.; Jafferbhoy H. M.; Jenkinson P. W.; Lam W. L.; Lyons M.; Macdonald J. C.; MacMaster M.; Mowat C.; Naismith G. D.; Potts L. F.; Saffouri E.; Seenan J. P.; Sengupta A.; Shasi P.; Sutherland D. I.; Todd J. A.; Veryan J.; Watson A. J. M.; Watts D. A.; Jones G. R.; Lees C. W.

首页> 外文期刊>Journal of Crohn’s & colitis >Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort

【24h】

Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort

机译：Vedolizumab治疗炎症性肠病的真实效力和安全性：苏格兰Vedolizumab队列

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background & Aims: Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis. The aims of this study were to establish the real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease.

机译：背景与目的：韦多利珠单抗是一种抗a4b7单克隆抗体，获准用于治疗中重度克罗恩病和溃疡性结肠炎。本研究的目的是确定韦多利单抗治疗炎症性肠病的真实有效性和安全性。

著录项

来源
《Journal of Crohn’s & colitis》 |2019年第9期|共10页
作者
Plevris N.; Chuah C. S.; Allen R. M.; Arnott I. D.; Brennan P. N.; Chaudhary S.; Churchhouse A. M. D.; Din S.; Donoghue E.; Gaya D. R.; Groome M.; Jafferbhoy H. M.; Jenkinson P. W.; Lam W. L.; Lyons M.; Macdonald J. C.; MacMaster M.; Mowat C.; Naismith G. D.; Potts L. F.; Saffouri E.; Seenan J. P.; Sengupta A.; Shasi P.; Sutherland D. I.; Todd J. A.; Veryan J.; Watson A. J. M.; Watts D. A.; Jones G. R.; Lees C. W.;
展开▼
作者单位

Western Gen Hosp Edinburgh IBD Unit Edinburgh EH4 2XU Midlothian Scotland;

Western Gen Hosp Edinburgh IBD Unit Edinburgh EH4 2XU Midlothian Scotland;

Glasgow Royal Infirm Dept Gastroenterol Glasgow Lanark Scotland;

Western Gen Hosp Edinburgh IBD Unit Edinburgh EH4 2XU Midlothian Scotland;

Ninewells Hosp Dept Gastroenterol Dundee Scotland;

Univ Hosp Hairmyres Dept Gastroenterol E Kilbride Lanark Scotland;

Victoria Hosp Dept Gastroenterol Kirkcaldy Scotland;

Western Gen Hosp Edinburgh IBD Unit Edinburgh EH4 2XU Midlothian Scotland;

Forth Valley Royal Hosp Dept Gastroenterol Larbert Scotland;

Glasgow Royal Infirm Dept Gastroenterol Glasgow Lanark Scotland;

Ninewells Hosp Dept Gastroenterol Dundee Scotland;

Victoria Hosp Dept Gastroenterol Kirkcaldy Scotland;

Western Gen Hosp Edinburgh IBD Unit Edinburgh EH4 2XU Midlothian Scotland;

Glasgow Royal Infirm Dept Gastroenterol Glasgow Lanark Scotland;

Western Gen Hosp Edinburgh IBD Unit Edinburgh EH4 2XU Midlothian Scotland;

Queen Elizabeth Univ Hosp Dept Gastroenterol Glasgow Lanark Scotland;

Glasgow Royal Infirm Dept Gastroenterol Glasgow Lanark Scotland;

Ninewells Hosp Dept Gastroenterol Dundee Scotland;

Royal Alexandra Hosp Dept Gastroenterol Paisley Renfrew Scotland;

Raigmore Hosp Dept Gastroenterol Inverness Scotland;

Glasgow Royal Infirm Dept Gastroenterol Glasgow Lanark Scotland;

Queen Elizabeth Univ Hosp Dept Gastroenterol Glasgow Lanark Scotland;

Victoria Hosp Dept Gastroenterol Kirkcaldy Scotland;

Ninewells Hosp Dept Gastroenterol Dundee Scotland;

Univ Hosp Hairmyres Dept Gastroenterol E Kilbride Lanark Scotland;

Ninewells Hosp Dept Gastroenterol Dundee Scotland;

Glasgow Royal Infirm Dept Gastroenterol Glasgow Lanark Scotland;

Raigmore Hosp Dept Colorectal Surg Inverness Scotland;

Forth Valley Royal Hosp Dept Gastroenterol Larbert Scotland;

Western Gen Hosp Edinburgh IBD Unit Edinburgh EH4 2XU Midlothian Scotland;

Western Gen Hosp Edinburgh IBD Unit Edinburgh EH4 2XU Midlothian Scotland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类杆菌传染病;
关键词
Vedolizumab; real-world; Crohn's disease; ulcerative colitis; mucosal healing;

机译：Vedolizumab;现实世界;克罗恩病;溃疡性结肠炎;粘膜愈合;

相似文献

外文文献
中文文献
专利

1. Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center [J] . Chaitanya Allamneni, Krishna Venkata, Huifeng Yun, Gastroenterology Research . 2018,第1期

机译：Vedolizumab与Infliximab诱导疗法在溃疡性结肠炎中的比较有效性：第三级炎症性肠病中心的真实队列研究
2. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease [J] . Stefan Schreiber, Axel Dignass, Laurent Peyrin-Biroulet, Journal of gastroenterology . 2018,第9期

机译：荟萃分析系统综述：炎症肠病患者的vedolizumab的实际效力和安全性
3. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study [J] . Lenti Marco Vincenzo, Levison Scott, Eliadou Elena, Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver . 2018,第12期

机译：成人炎症肠病成人患者患者的现实世界，长期经验，vedolizumab患者：十字路口研究
4. How to Represent the Decision Process in a Medication Plan: the Case of the Swiss Cohort of Inflammatory Bowel Diseases [C] . Frederic EHRLER, Philippe BAUMANN, Christian LOVIS Medical Informatics in Europe Conference. . 2015

机译：如何代表药物计划中的决策过程：瑞士罪恶疾病的案子
5. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. [D] . DeBruyn, Jennifer Carole Cheung. 2010

机译：炎性肠病患儿接种流感疫苗的免疫原性和安全性。
6. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease [O] . Stefan Schreiber, Axel Dignass, Laurent Peyrin-Biroulet, -1

机译：荟萃分析的系统评价：维多珠单抗在炎症性肠病患者中的现实有效性和安全性
7. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort [O] . N Plevris, C S Chuah, R M Allen, 2019

机译：Vedolizumab治疗炎症性肠病的真实效力和安全性：苏格兰vedolizumab队列
8. Treatment of Inflammatory Bowel Disease through Induction of Indoleamine 2.3-Dioxygenase. [R] . Gurtner, G., Gurtner, N., Stenson, W. F. 2004

机译：通过诱导吲哚胺2.3-双加氧酶治疗炎症性肠病。

Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort

摘要

著录项

相似文献

相关主题

期刊订阅